Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus

Programmed death-1 (PD-1) was shown to deliver an inhibitory signal after binding to its ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). Recently, up-regulated expression of PD-1 molecule and/or its ligands was demonstrated in human diseases including rheumatoid arthritis and inflammatory colitis. The stud...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Ming-Fei, Weng, Chia-Tse, Weng, Meng-Yu
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744882/
https://www.ncbi.nlm.nih.gov/pubmed/19759858
http://dx.doi.org/10.1155/2009/406136
_version_ 1782171934066212864
author Liu, Ming-Fei
Weng, Chia-Tse
Weng, Meng-Yu
author_facet Liu, Ming-Fei
Weng, Chia-Tse
Weng, Meng-Yu
author_sort Liu, Ming-Fei
collection PubMed
description Programmed death-1 (PD-1) was shown to deliver an inhibitory signal after binding to its ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). Recently, up-regulated expression of PD-1 molecule and/or its ligands was demonstrated in human diseases including rheumatoid arthritis and inflammatory colitis. The study aimed to investigate the expression and function of PD-1 and PD-1 ligands on circulating T cells, B cells and monocytes from patient with systemic lupus erythematosus (SLE). The results showed that patients with SLE had significantly increased percentages of PD-1-expressing CD3(+)T cells and CD19(+)B cells, PD-L1-expressing CD19(+)B cells and PD-L2-expressing CD14(+)B monocytes. In selected SLE patients and normal subjects, functional study of PD-1/ PD-1 ligands pathway on the production of cytokines by stimulated PBMC was examined. Blockages of PD-1 or PD-1 ligands substantially increased the production of IL-2, IFN-γ and IL-10, the amplitude of increase roughly ranged from one to three times. There were no significant differences of the enhancing effects on cytokine production by blockage of PD-1/PDL pathway between SLE patients and normal subjects. The study indicates that there are no intrinsically defective expression and function of PD-1 and PD-1 ligands on PBMC in patients with SLE.
format Text
id pubmed-2744882
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-27448822009-09-16 Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus Liu, Ming-Fei Weng, Chia-Tse Weng, Meng-Yu J Biomed Biotechnol Research Article Programmed death-1 (PD-1) was shown to deliver an inhibitory signal after binding to its ligands, PD-L1 (B7-H1) or PD-L2 (B7-DC). Recently, up-regulated expression of PD-1 molecule and/or its ligands was demonstrated in human diseases including rheumatoid arthritis and inflammatory colitis. The study aimed to investigate the expression and function of PD-1 and PD-1 ligands on circulating T cells, B cells and monocytes from patient with systemic lupus erythematosus (SLE). The results showed that patients with SLE had significantly increased percentages of PD-1-expressing CD3(+)T cells and CD19(+)B cells, PD-L1-expressing CD19(+)B cells and PD-L2-expressing CD14(+)B monocytes. In selected SLE patients and normal subjects, functional study of PD-1/ PD-1 ligands pathway on the production of cytokines by stimulated PBMC was examined. Blockages of PD-1 or PD-1 ligands substantially increased the production of IL-2, IFN-γ and IL-10, the amplitude of increase roughly ranged from one to three times. There were no significant differences of the enhancing effects on cytokine production by blockage of PD-1/PDL pathway between SLE patients and normal subjects. The study indicates that there are no intrinsically defective expression and function of PD-1 and PD-1 ligands on PBMC in patients with SLE. Hindawi Publishing Corporation 2009 2009-09-16 /pmc/articles/PMC2744882/ /pubmed/19759858 http://dx.doi.org/10.1155/2009/406136 Text en Copyright © 2009 Ming-Fei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Liu, Ming-Fei
Weng, Chia-Tse
Weng, Meng-Yu
Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title_full Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title_fullStr Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title_full_unstemmed Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title_short Variable Increased Expression of Program Death-1 and Program Death-1 Ligands on Peripheral Mononuclear Cells Is Not Impaired in Patients with Systemic Lupus Erythematosus
title_sort variable increased expression of program death-1 and program death-1 ligands on peripheral mononuclear cells is not impaired in patients with systemic lupus erythematosus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2744882/
https://www.ncbi.nlm.nih.gov/pubmed/19759858
http://dx.doi.org/10.1155/2009/406136
work_keys_str_mv AT liumingfei variableincreasedexpressionofprogramdeath1andprogramdeath1ligandsonperipheralmononuclearcellsisnotimpairedinpatientswithsystemiclupuserythematosus
AT wengchiatse variableincreasedexpressionofprogramdeath1andprogramdeath1ligandsonperipheralmononuclearcellsisnotimpairedinpatientswithsystemiclupuserythematosus
AT wengmengyu variableincreasedexpressionofprogramdeath1andprogramdeath1ligandsonperipheralmononuclearcellsisnotimpairedinpatientswithsystemiclupuserythematosus